Access to Healthcare on a Global Scale
We’re committed to providing patients and their families with transformative medicines, as we aim to understand the needs and experiences of those we serve.
Clinical Trials
Psoriasis
EDP1815
A Phase 2 study investigating the effect of EDP1815 in the treatment of mild to moderate plaque psoriasis
EDP2939
Phase 1/2, randomized, placebo-controlled trial conducted in two parts. Part A will evaluate the safety and tolerability of EDP2939 in healthy volunteers. Part B will evaluate the safety, tolerability and preliminary efficacy in adults with moderate psoriasis. The primary endpoint of Part B is the superiority of EDP2939 as compared to placebo on the proportion of participants with moderate psoriasis achieving a PASI-50 response.
Atopic Dermatitis
EDP1815
A Phase 2 study investing the effect of EDP1815 in the treatment of mild, moderate and severe atopic dermatitis
Learn more about our EDP1815 atopic dermatitis clinical trial
If you have questions about our clinical trials, please contact clinicaltrials@evelobio.com.
Our Commitment
Read about our commitment to patients from some members of our team.

Contact Us
We Want to Hear From You
Let’s start the conversation. For inquiries or requests for more information, reach out.